恶性血液病及实体瘤患者sIL-2R的动态研究

The dynamical investigation of serum sIL-2R level in hematologic neoplasmas and solid tumors

目的探讨恶性血液病及其他恶性肿瘤患者血清sIL 2R动态变化的临床意义。方法用双抗体酶联免疫吸附法 (ELISA)对 96例各类恶性血液病及其他肿瘤化疗前后动态观察其血清中sIL 2R水平。结果化疗前各组病人sIL 2R水平均显著高于正常对照组 (P <0 0 1 ) ;化疗后各组sIL 2R均明显降低 ,自身配对比较 ,差异有显著性 (P <0 0 1 ) ,但仍高于正常组 ;急性白血病化疗后sIL 2R下降幅度 >2 0 %者其CR率较 <2 0 %者高 (P <0 0 1 ) ;sIL 2R水平与骨髓白血病细胞的量呈正相关 (r =0 6 6 8,P <0 0 0 1 )。结论动态观察sIL 2R水平对评估病情及早期预测疗效有一定价值。

Objective To explore the dynamic changes of serum sIL 2R levels in hematologic neoplasmas and other tumors and clinical value. Methods The serum level of sIL 2R were measured by ELISA in 96 cases with hematologic and other malignant disesases before and after chemotherapy. Results Before chemotherapy the serum levels of sIL 2R in every groups patients were significantly higher than that of normal value ( P <0.01), after chemotherapy that the levels were markedly reduced than before but still higher than normel value. The patients with acute leukemia after chemotherapy if their serum sIL 2R values were reduced>20% than before, that their CR rate was higher than those who<20% ( P <0.01). The level of sIL 2R was positive corelate with the number of bone marrow blast ( r =0.668 P <0.001). Conclusion The change of serum sIL 2R level may be used as an effective clinical prognostic marker.